Expression of Epidermal Growth Factor Receptor, Apomucins, Matrix Metalloproteinases, and P53 in Rat and Human Cholangiocarcinoma: Appraisal of an Animal Model of Cholangiocarcinoma

Overview

Journal Ann Surg

Specialty General Surgery

Date 2004 Jun 24

PMID 15213623

Citations 15

Authors

Yi-Yin Jan

Ta-Sen Yeh

Jun-Nan Yeh

Horng-Ren Yang

Miin-Fu Chen

Affiliations

Soon will be listed here.

Abstract

Objective: We sought to determine the expression of molecular markers in an animal model of cholangiocarcinoma compared with those in human cholangiocarcinoma.

Summary Background Data: Cholangiocarcinoma is a rare disease characterized by early intrahepatic and extrahepatic spread, which seriously limits the efficacy of surgery. Establishing an experimental model to study the cholangiocarcinogenesis is desirable.

Methods: Sprague-Dawley rats weighing 300 +/- 50 g were used for the study group. The animals were given 0.3% thioacetamide in tap water continuously. Thirty mass-forming peripheral cholangiocarcinoma patients also were studied. Expression of epidermal growth factor receptor (EGFR), MUC1, MUC2, MUC5AC, MMP-2, MMP-9, and p53 in both human and experimental rat cholangiocarcinoma was examined using immunohistochemistry.

Results: Using thioacetamide 0.3% as a hepatoxin to induce cholangiocarcinoma in rats, microfoci of cancerous cells were detected from 12 weeks, and all experimental rats displayed diffuse mass-forming cholangiocarcinoma after 24 weeks. EGFR was strongly expressed in 14 (47%) of 30 human cholangiocarcinoms and 24 (100%) of 24 rat cholangiocarcinomas, respectively. MUC1 was strongly expressed in all human and rat cholangiocarcinomas, whereas MUC2 and MUC5AC were focally and weakly expressed. MMP-2 and MMP-9 were strongly expressed in 22 (73%) of 30 human cholangiocarcinomas and 24 (100%) of 24 rat cholangiocarcinomas, respectively. p53 overexpression was detected in 9 (30%) of 30 human cholangiocarcinoma and none of the rat cholangiocarcinoma, respectively.

Conclusions: The expression of EGFR, apomucins, MMPs, and p53 in rat cholangiocarcinoma was strongly homologous to human cholangiocarcinoma. Thioacetamide-induced cholangiocarcinoma in rats provides an excellent model for investigating cholangiocarcinogenesis in vivo.

Citing Articles

Reflections on Drivers for the Emergence and Spread of Antimicrobial Resistant Bacteria Detected from Chickens reared on Commercial Layer Farms in Mukono District, Uganda.

Kakooza S, Tayebwa D, Njalira K, Kayaga E, Asiimwe I, Komugisha M Vet Med (Auckl). 2023; 14:209-219.

PMID: 38084340 PMC: 10710787. DOI: 10.2147/VMRR.S418624.

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.

Pan Y, Wu C, Chen M, Huang W, Shih H, Lan K Vaccines (Basel). 2020; 8(4).

PMID: 33255375 PMC: 7712087. DOI: 10.3390/vaccines8040703.

Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination.

Ueda J, Yoshida H, Mamada Y, Taniai N, Yoshioka M, Hirakata A Oncol Lett. 2018; 16(5):6677-6684.

PMID: 30405808 PMC: 6202532. DOI: 10.3892/ol.2018.9479.

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.

Lin G, Lin K, Wang F, Chen T, Yen T, Yeh T Dis Model Mech. 2018; 11(8).

PMID: 29666220 PMC: 6124555. DOI: 10.1242/dmm.033050.

Animal models of cholangiocarcinoma.

Loeuillard E, Fischbach S, Gores G, Ilyas S Biochim Biophys Acta Mol Basis Dis. 2018; 1865(5):982-992.

PMID: 29627364 PMC: 6177316. DOI: 10.1016/j.bbadis.2018.03.026.

References

Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H . Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 1997; 57(10):2055-60. View

Sato H, Seiki M . Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993; 8(2):395-405. View

Teh M, Wee A, Raju G . An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer. 1994; 74(5):1542-5. DOI: 10.1002/1097-0142(19940901)74:5<1542::aid-cncr2820740508>3.0.co;2-u. View

Yonezawa S, Sueyoshi K, Nomoto M, Kitamura H, Nagata K, Arimura Y . MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum Pathol. 1997; 28(3):344-52. DOI: 10.1016/s0046-8177(97)90134-9. View

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

Porchet N, Buisine M, Desseyn J, Moniaux N, Nollet S, Degand P . [MUC genes: a superfamily of genes? Towards a functional classification of human apomucins]. J Soc Biol. 2000; 193(1):85-99. View

Chen M, Jan Y, Chen T . Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases. Ann Surg. 1998; 227(1):63-9. PMC: 1191174. DOI: 10.1097/00000658-199801000-00010. View

Higashi M, Yonezawa S, Ho J, Tanaka S, Irimura T, Kim Y . Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 1999; 30(6):1347-55. DOI: 10.1002/hep.510300609. View

FITZHUGH O, Nelson A . Liver Tumors in Rats Fed Thiourea or Thioacetamide. Science. 1948; 108(2814):626-8. DOI: 10.1126/science.108.2814.626. View

10.

Yeh T, Jan Y, Tseng J, Chiu C, Chen T, Hwang T . Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol. 2000; 95(2):432-40. DOI: 10.1111/j.1572-0241.2000.01763.x. View

11.

Chen T, Nakanuma Y, Zen Y, Chen M, Jan Y, Yeh T . Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001; 34(4 Pt 1):651-8. DOI: 10.1053/jhep.2001.28199. View

12.

Endo K, Yoon B, Pairojkul C, Demetris A, Sirica A . ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002; 36(2):439-50. DOI: 10.1053/jhep.2002.34435. View

13.

Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J . Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer. 1999; 80(7):1069-74. PMC: 2363034. DOI: 10.1038/sj.bjc.6690465. View

14.

Shirabe K, Shimada M, Kajiyama K, Hasegawa H, Gion T, Ikeda Y . Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery. 1999; 126(5):842-6. View

15.

Chen M, Jan Y, Wang C, Hwang T, Jeng L, Chen S . A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993; 71(8):2461-5. DOI: 10.1002/1097-0142(19930415)71:8<2461::aid-cncr2820710806>3.0.co;2-7. View

16.

Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A . p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995; 22(3):774-9. View

17.

Washington K, Gottfried M . Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver. 1996; 16(2):99-104. DOI: 10.1111/j.1600-0676.1996.tb00712.x. View

18.

Al-Bader A, Mathew T, Abul H, Al-Sayer H, Singal P, Dashti H . Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol Cell Biochem. 2000; 208(1-2):1-10. DOI: 10.1023/a:1007082515548. View

19.

Sirica A, Lai G, Endo K, Zhang Z, Yoon B . Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis. 2002; 22(3):303-13. DOI: 10.1055/s-2002-34507. View

20.

Terada T, Okada Y, Nakanuma Y . Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996; 23(6):1341-4. DOI: 10.1053/jhep.1996.v23.pm0008675149. View